ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Microorganisms in Vertebrate Digestive Systems
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1655522
This article is part of the Research TopicRodent Model Organisms: Therapeutic Treatments and Drugs Interaction with the Gut Microbiome, Volume IIView all 4 articles
Sitagliptin ameliorates microbial dysbiosis and enhances gut barrier integrity in streptozotocin-induced type 2 diabetic rats
Provisionally accepted
- 1Chongqing General Hospital, Chongqing, China
- 2The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
- 3Chongqing Medical University, Chongqing, China
- 4Chongqing City Hospital of Traditional Chinese Medicine, Chongqing, China
- 5Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has demonstrated efficacy in the management of type 2 diabetes mellitus (T2DM). This study aimed to investigate the effects of sitagliptin on gut microbial composition and gut barrier integrity in a streptozotocin (STZ)-induced rat model of T2DM. Methods: Sprague-Dawley rats were randomly divided into four groups (n = 6 per group): a T2DM group induced by high-fat diet (HFD) and STZ injection; a T2DM group treated with oral sitagliptin at 10 mg/kg/day for 12 weeks (T2DM-Sit); a normal diet control group (ND); and a normal diet group treated with sitagliptin (ND-Sit). Fecal samples were collected for 16S rRNA gene sequencing to analyze gut microbial composition and diversity. Intestinal tissues were assessed for tight junction protein expression via immunohistochemistry and western blot. Result: Alpha index metrics, including observed feature number and Shannon index, were significantly decreased in the T2DM group compared to the ND group. Sitagliptin treatment led to a significant restoration of these indices. Principal coordinate analysis based on Bray-Curtis distances revealed distinct clustering between the ND and T2DM groups, with sitagliptin shifting the microbial profile of diabetic rats toward that of healthy controls. Sitagliptin treatment increased the relative abundance of Lactobacillus, Ruminococcus, Streptococcus, Klebsiella, Clostridium_IV, and Romboutsia, while reducing levels of Alloprevotella and Parasutterella, effectively reversing the dysbiotic changes observed in T2DM. Additionally, sitagliptin modulated microbial metabolic pathways, restructured the gut microbial network, and promoted short-chain fatty acid production. Histological and western blot analysis revealed enhanced expression of the tight junction protein ZO-1 and increased numbers of mucin-secreting goblet cells, indicating improved gut barrier integrity. Conclusion: Sitagliptin effectively ameliorates gut microbial dysbiosis and restores intestinal barrier function in STZ-induced T2DM rats. These findings provide novel insights into the gut-related therapeutic effects of sitagliptin and underscore its potential in restoring gut homeostasis in T2DM.
Keywords: sitagliptin, type 2 diabetes mellitus, Gut Microbiota, gut microbial network, intestinal barrier function
Received: 30 Jun 2025; Accepted: 28 Aug 2025.
Copyright: © 2025 Chang, Zhou, Zhou, Liang, Li and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mingyuan Tian, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.